Anne-Sophie Mutter
Photo: The Japan Art Association / The Sankei Shumbun (2019)
Anne-Sophie Mutter is to become the next president of the German Cancer Aid - an organisation with personal significance for her. The German violinist’s first husband, the lawyer Detlef Wunderlich, died of lung cancer in 1995, leaving her with their two young children, both aged under three at the time.
Speaking to RTL.de, Mutter said: ‘I actually found oncology to be downright medieval in the 1990s. A person is not a car that goes through the TÜV test. And back then this diagnosis was presented to me like a TÜV test certificate with a definite end date.’ She continued: ’I still see a need for action in terms of communication skills between doctor and patient.’
Date Time
Stirring up Conflicts in Tumour Cells
With two commercially available inhibitors, the cell cycle of the cancer cells in the childhood tumour neuroblastoma can be disrupted at a key point causing tumour cell death.
Survival curve of the TH-MYCN mouse model during long-term treatment with Aurora-A inhibitor (purple), ATR inhibitor (blue) or the combination of both agents (red). It is clearly visible that the combination therapy prolongs survival time. (Image: Gabriele Büchel / Universität Würzburg)
Neuroblastomas are malignant solid tumours that occur mainly in early childhood. They arise from degenerated immature cells of the sympathetic nervous system.
Press release content from Business Wire. The AP news staff was not involved in its creation.
NOXXON Appoints Leading Pancreatic Cancer Experts to Scientific Advisory Board
February 8, 2021 GMT
Regulatory News:
NOXXON Pharma N.V.
(Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the appointment of four leading pancreatic cancer experts to its Scientific Advisory Board (SAB). Led by the newly appointed Chair, Dr. Jose Saro, the SAB will provide strategic and scientific counsel to NOXXON’s clinical programs in this indication.
“These prominent research leaders bring long-standing clinical expertise, cutting-edge scientific knowledge, and a track record of successfully developing new drugs to treat this devastating disease. They fully understand the challenges of developing new drugs for pancreas cancer where the tumor microenvironment plays a large role in resisting ant